International professional education covering cannabinoid science, clinical practice, evidence appraisal and regulatory frameworks.
The Institute's flagship 12-module course in cannabinoid science, safety, evidence appraisal, clinical contexts and prescribing principles. The final three case-study modules are in development, with content being finalised.
Focused, self-paced modules across pharmacology, cannabinoids and clinical indications.
Medicinal cannabis is emerging as a legitimate and legal therapeutic domain in many jurisdictions, but evidence varies substantially by cannabinoid, product, formulation, dose, route and clinical indication. Historical use does not replace modern evidence appraisal. Professionals need sufficient knowledge to recognise potential benefits and limitations, adverse effects, contraindications and interactions, and to respond within their scope and local law.
Our teaching is directed by Professor Kylie O'Brien — academic, clinical researcher and author of three Springer titles. Further educators are being confirmed and added as each joins the teaching team.
Every module is shaped by academic leadership and clinical experience — spanning ECS biology, clinical pharmacology, pain, mental health, women's health and regulatory science.
Research into cannabinoid therapy is developing rapidly, although the quantity and quality of evidence vary substantially by cannabinoid, formulation and clinical indication.
Patients and colleagues are asking informed questions in every specialty.
Regulatory landscapes are shifting across most major jurisdictions.
Rigorous appraisal is essential to separate signal from noise.
Understanding benefits, limitations, contraindications and interactions.
Explore the Foundations Course in Cannabinoid Therapy (USD $500) and individual modules (USD $100 when available), including focused modules on regulation.
